Chronic Myeloid Leukemia News and Research

RSS
Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.
Pfizer to present data on hematology portfolio at ASH Annual Meeting

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Rush University enrolls first U.S. patient in international clinical trial for melanoma

Rush University enrolls first U.S. patient in international clinical trial for melanoma

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

ARIAD reports $20.4 million net loss for third quarter 2010

ARIAD reports $20.4 million net loss for third quarter 2010

CytRx reports $4.4 million net loss for third quarter 2010

CytRx reports $4.4 million net loss for third quarter 2010

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

New microfluidic in vitro kinase radioassay improves efficiency to detect cancer growth

New microfluidic in vitro kinase radioassay improves efficiency to detect cancer growth

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

Immune system may play a role in cancer therapies: Study

Immune system may play a role in cancer therapies: Study

ARIAD prices common stock public offering

ARIAD prices common stock public offering

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer

ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer

Cephalon signs convertible note subscription agreement with ChemGenex Pharmaceuticals

Cephalon signs convertible note subscription agreement with ChemGenex Pharmaceuticals

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Cepheid collaborates with Novartis to commercialize BCR-ABL monitoring test

Cepheid collaborates with Novartis to commercialize BCR-ABL monitoring test

Otsuka opens Canadian operations

Otsuka opens Canadian operations

Novartis applauds declaration of CML Awareness Day in Canada

Novartis applauds declaration of CML Awareness Day in Canada

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.